Studies of NVP-BEZ235 in melanoma

Current Cancer Drug Targets

Volumn 13, Issue 2, 2013, Pages 165-174

  Sznol, Joshua A ^a   Jilaveanu, Lucia B ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Mammalian target of rapamycin; Melanoma; Phosphatidylinositol 3 kinase

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4, 6 DIMORPHOLINO 1, 3, 5 TRIAZINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO [3', 2':4, 5] FURO [3, 2 D] PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL) IMIDAZO [5, 1 F] [1, 2, 4] TRIAZIN 7 YL) CYCLOHEXANECARBOXYLIC ACID; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [2 (4 AMINO 1, 2, 5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO [4, 5 C] PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 DIALLYLAMINOMETHYLENE 1, 3, 4, 7, 10, 11, 12, 13, 14, 15, 16, 17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10, 13 DIMETHYL 3, 7, 17 TRIOXO 2 OXACYCLOPENTA [A] PHENANTHREN 11 YL ACETATE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AFURESERTIB; AMG 319; API 1; ARRY 438162; BAY 806946; BUPARLISIB; BYL 719; COPANLISIB; DS 7423; EDELFOSINE; EVEROLIMUS; GSK 2110189; IC87 114; IDELALISIB; IPI 145; ISC 4; MILTEFOSINE; OXA 01; PALOMID 529; PBISE; PERIFOSINE; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PICTILISIB; PKI 587; PROTEIN MDM2; PROTEIN P110; PWT 33597; RAPAMYCIN; SAR 245409; SF 1124; TEMSIROLIMUS; TG 100115; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765;

APOPTOSIS; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CELL VIABILITY; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; METASTASIS; METASTATIC MELANOMA; MULTIPLE CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMIDAZOLES; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84876865386     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313020006     Document Type: Review

References (102)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward E. Cancer statistics. 2010. CA Cancer J. Clin. 2010, 60 (5), 277-300.
2. Rigel, D.S. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin. Proc. 1997, 72 (4), 367-371.
3. Jemal, A.; F. Bray, M.; Center, M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61 (2), 69-90.
4. Jilaveanu, L. B.; Aziz, S. A.; Kluger, H. M. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol. 2009, 27 (6), 614-625.
5. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T. McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364 (26), 2507-2516.
6. Hodi, F. S.; O'Day, S. J.; McDermott; D. F. Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363 (8), 711-723.
7. Robert, C.; Thomas, L.; Bondarenko, I.; O'Day, S.; M D, J. W.; Garbe, C.; Lebbe, J.; Baurain, C.; Testori, J. F.; Grob, A.; Davidson, J. J.; Richards, N.; Maio, M.; Hauschild, A.; Miller, W. H. Jr.; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T. T.; Humphrey, R.; Hoos, A.; Wolchok, J. D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364 (26), 2517-2526.
8. Rubinstein, J. C.; Sznol, M.; Pavlick, A. C.; Ariyan, S.; Cheng, E.; Bacchiocchi, A.; Kluger, H. M.; Narayan, D.; Halaban, R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 2010, 8, 67.
9. Halaban, R.; Zhang, W.; Bacchiocchi, A.; Cheng, E.; Parisi, F.; Ariyan, S.; Krauthammer, M.; McCusker, J. P.; Kluger, Y.; Sznol, M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010, 23 (2), 190-200.
10. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee, H.; Chen, Z.; Lee, M. K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S. F.; McArthur, G.; Sosman, J. A.; Ribas, A.; Lo, R. S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468 (7326), 973-977.
11. Johannessen, C. M.; Boehm, J. S.; Kim, S. Y.; Thomas, S. R.; Wardwell, L.; Johnson, L. A.; Emery, C. M.; Stransky, N.; Cogdill, A. P.; Barretina, J.; Caponigro, G.; Hieronymus, H.; Murray, R. R.; Salehi-Ashtiani, K.; Hill, D. E.; Vidal, M.; Zhao, J. J.; Yang, X.; Alkan, O.; Kim, S.; Harris, J. L.; Wilson, C. J.; Myer, V. E.; Finan, P. M.; Root, D. E.; Roberts, T. M.; Golub, T.; Flaherty, K. T.; Dummer, R.; Weber, B. L.; Sellers, W. R.; Schlegel, R.; Wargo, J. A.; Hahn, W. C.; Garraway, L. A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468 (7326), 968-972.
12. Kluger, H. M.; Dudek, A. Z.; McCann, C.; Ritacco, J.; Southard, N.; Jilaveanu, L. B.; Molinaro, A.; Sznol, M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011, 117 (10), 2202-2208.
13. Woodman, S. E.; Trent, J. C.; Stemke-Hale, K.; Lazar, A. J.; Pricl, S.; Pavan, G. M.; Fermeglia, M.; Gopal, Y. N.; Yang, D.; Podoloff, D. A.; Ivan, D.; Kim, K. B.; Papadopoulos, N.; Hwu, P.; Mills, G. B.; Davies, M. A. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 2009, 8 (8), 2079-2085.
14. Hodi, F. S.; Friedlander, P.; Corless, C. L.; Heinrich, M. C.; Mac Rae, S.; Kruse, A.; Jagannathan, J.; Van den Abbeele, A. D.; Velazquez, E. F.; Demetri, G. D.; Fisher, D. E. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 2008, 26 (12), 2046-2051.
15. Dankort, D.; Curley, D. P.; Cartlidge, R. A.; Nelson, B.; Karnezis, A. N.; Damsky, W. E. Jr.; You, M. J.; DePinho, R. A.; McMahon, M.; Bosenberg, M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009, 41 (5), 544-552.
16. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7 (7), 1851-1863.
17. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7 (8), 606-619.
18. Dbouk, H. A.; Backer, J. M. A beta version of life: p110beta takes center stage. Oncotarget 2010, 1 (8), 729-733.
19. Aziz, S. A.; Davies, M.; Pick, E.; Zito, C.; Jilaveanu, L.; Camp, R. L.; Rimm, D. L.; Kluger, Y.; Kluger, H. M. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin. Cancer Res. 2009, 15 (9), 3029-3036.
20. Gaidarov, I.; Smith, M. E.; Domin, J.; Keen, J. H. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell. 2001, 7 (2), 443-449.
21. Nobukuni, T.; Joaquin, M.; Roccio, M.; Dann, S. G.; Kim, S. Y.; Gulati, P.; Byfield, M. P.; Backer, J. M.; Natt, F.; Bos, J. L.; Zwartkruis, F. J.; Thomas, G. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OHkinase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (40), 14238-14243.
22. Wurmser, A. E.; Emr, S. D. Novel PtdIns(3)P-binding protein Etf1 functions as an effector of the Vps34 PtdIns 3-kinase in autophagy. J. Cell Biol. 2002, 158 (4), 761-772.
23. Sly, L. M.; Rauh, M. J.; Kalesnikoff, J.; Buchse, T.; Krystal, G. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp. Hematol. 2003, 31 (12), 1170-1181.
24. Tamir, I.; Stolpa, J. C.; Helgason, C. D.; Nakamura, K.; Bruhns, P.; Daeron M.; Cambier J. C. The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 2000, 12 (3), 347-358.
25. Bogenrieder, T.; Herlyn, M. The molecular pathology of cutaneous melanoma. Cancer Biomark. 2011, 9 (1-6), 267-286.
26. Georgescu, M. M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cance. 2010, 1 (12), 1170-1177.
27. Hanada, M.; Feng, J.; Hemmings, B. A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta. 2004, 1697 (1-2), 3-16.
28. Nicholson, K. M.; Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14 (5), 381-395.
29. Keely, P. J.; Westwick, J. K.; Whitehead, I. P.; Der, C. J.; Parise, L. V. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997, 390 (6660), 632-636.
30. Shaw, L. M.; Rabinovitz, I.; Wang H. H.; Toker A.; Mercurio, A. M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997, 91 (7), 949-960.
31. Kim, D.; Kim, S.; Koh, H.; Yoon, S. O.; Chung, A. S.; Cho, K. S.; Chung, J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15 (11), 1953-1962.
32. Kang, S.; Denley, A.; Vanhaesebroeck, B.; Vogt, P. K. Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (5), 1289-1294.
33. Jia, S.; Liu, Z.; Zhang, S.; Liu P.; Zhang, L.; Lee, S. H.; Zhang J.; Signoretti, S.; Loda, M.; Roberts, T. M.; Zhao, J. J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454 (7205), 776-779.
34. Wee, S.; Wiederschain, D.; Maira, S. M.; Loo, A.; Miller, C.; deBeaumont, R.; Stegmeier, F.; Yao, Y. M.; Lengauer, C. PTENdeficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (35), 13057-13062.
35. Duronio, V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008, 415 (3), 333-344.
36. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296 (5573), 1655-1657.
37. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4 (12), 988-1004.
38. Elfiky, A. A.; Aziz, S. A.; Conrad, P. J.; Siddiqui, S.; Hackl, W.; Maira, M.; Robert, C. L.; Kluger, H. M. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J. Transl. Med. 2011, 9, 133.
39. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304 (5670), 554.
40. Isakoff, S.J.; Engelman, J. A.; Irie, H. Y.; Luo, J.; Brachmann, S. M.; Pearline, R. V.; Cantley, L. C.; Brugge, J. S. Breast cancerassociated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65 (23), 10992-11000.
41. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (3), 802-807.
42. Samuels, Y.; Diaz, L. A. Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7 (6), 561-573.
43. Zhao, J. J.; Liu, Z.; Wang, L.; Shin, E.; Loda, M. F.; Roberts, T. M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (51), 18443-18448.
44. Janku, F.; Lee, J. J.; Tsimberidou, A. M.; Hong, D. S.; Naing, A.; Falchook, G. S.; Fu, S.; Luthra, R.; Garrido-Laguna, I.; Kurzrock, R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. Plos One 2011, 6 (7), e22769.
45. Stahl, J. M.; Cheung, M.; Sharma, A.; Trivedi, N. R.; Shanmugam, S.; Robertson, G. P. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003, 63 (11), 2881-2890.
46. Tsao, H.; Zhang, X.; Benoit, E.; Haluska, F. G. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16 (26), 3397-3402.
47. Zhou, X.P.; Gimm, O.; Hampel, H.; Niemann, T.; Walker, M. J.; Eng, C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 2000, 157 (4), 1123-1128.
48. Sigalotti, L.; Covre, A.; Fratta, E.; Parisi, G.; Colizzi, F.; Rizzo, A.; Danielli, R.; Nicolay, H. J.; Coral, S.; Maio, M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J. Transl. Med. 2010, 8, 56.
49. Sigalotti, L.; Fratta, E.; Coral, S.; Cortini, E.; Covre, A.; Nicolay, H. J.; Anzalone, L.; Pezzani, L.; Di Giacomo, A. M.; Fonsatti, E.; Colizzi, F.; Altomonte, M.; Calabro, L.; Maio, M. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J. Cell Physiol. 2007, 212 (2), 330-344.
50. Lahtz, C.; Stranzenbach, R.; Fiedler, E.; Helmbold, P.; Dammann, R. H. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J. Invest. Dermatol. 2010, 130 (2), 620-622.
51. Tsao, H.; Goel, V.; Wu, H.; Yang, G.; Haluska, F. G. Genetic interaction between NRAS and BRAF mutations and PTEN/ MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004, 122 (2), 337-341.
52. Paraiso, K. H.; Xiang, Y.; Rebecca, V. W.; Abel, E. V.; Chen, Y. A.; Munko, A. C.; Wood, E.; Fedorenko, I. V.; Sondak, V. K.; Anderson, A. R.; Ribas, A.; Palma, M. D.; Nathanson, K. L.; Koomen, J. M.; Messina, J. L.; Smalley, K.S. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71 (7), 2750-2760.
53. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28 (6), 1075-1083.
54. Curtin, J. A.; Stark, M. S.; Pinkel, D.; Hayward, N. K.; Bastian, B. C. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Invest. Dermatol. 2006, 126 (7), 1660-1663.
55. Davies, M. A.; Stemke-Hale, K.; Tellez, C.; Calderone, T. L.; Deng, W.; Prieto, V. G.; Lazar, A. J.; Gershenwald, J. E.; Mills, G. B. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 2008, 99 (8), 1265-1268.
56. Omholt, K.; Krockel, D.; Ringborg, U.; Hansson, J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 2006, 16 (2), 197-200.
57. Goodall, J.; Wellbrock, C.; Dexter, T. J.; Roberts, K.; Marais, R.; and Goding, C. R. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell Biol. 2004, 24 (7), 2923-2931.
58. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445 (7130), 851-857.
59. Karbowniczek, M.; Spittle, C. S.; Morrison, T.; Wu, H.; Henske, E. P. mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol. 2008, 128 (4), 980-987.
60. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118 (9), 3065-3074.
61. Cheung, M.; Sharma, A.; Madhunapantula, S. V.; Robertson, G. P. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008, 68 (9), 3429-3439.
62. Jiang, C. C.; Lai, F.; Thorne, R. F.; Yang, F.; Liu, H.; Hersey, P.; Zhang, X. D. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 2011, 17 (4), 721-730.
63. Mirzoeva, O. K.; Das, D.; Heiser, L. M.; Bhattacharya, S.; Siwak, D.; Gendelman, R.; Bayani, N.; Wang, N. J.; Neve, R. M.; Guan, Y.; Hu, Z.; Knight, Z.; Feiler, H. S.; Gascard, P.; Parvin, B.; Spellman, P. T.; Shokat, K. M.; Wyrobek, A. J.; Bissell, M. J.; McCormick, F.; Kuo, W. L.; Mills, G. B.; Gray, J. W.; Korn, W. M. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69 (2), 565-572.
64. She, Q. B.; Halilovic, E.; Ye, Q.; Zhen, W.; Shirasawa, S.; Sasazuki, T.; Solit, D.B.; Rosen, N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010, 18 (1), 39-51.
65. Somanath, P. R.; Vijai, J.; Kichina, J. V.; Byzova, T.; Kandel, E. S. The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene 2009, 28 (25), 2365-2369.
66. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P. A.; Wooster, R.; Stratton, M. R.; Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62 (23), 6997-7000.
67. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417 (6892), 949-954.
68. van 't Veer, L. J.; Burgering, B. M.; Versteeg, R.; Boot, A. J.; Ruiter, D. J.; Osanto, S.; Schrier, P. I.; Bos, J. L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell Biol. 1989, 9 (7), 3114-3116.
69. Hocker, T.; Tsao, H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 2007, 28 (6), 578-588.
70. Rodriguez-Viciana, P.; Warne, P. H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M. J.; Waterfield, M. D.; Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370 (6490), 527-532.
71. Goel, V. K.; Lazar, A. J.; Warneke, C. L.; Redston, M. S.; Haluska, F. G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 2006, 126 (1), 154-160.
72. Carracedo, A.; Pandolfi, P. P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27 (41), 5527-5541.
73. Satyamoorthy, K.; Li, G.; Gerrero, M. R.; Brose, M. S.; Volpe, P.; Weber, B. L.; Van Belle, P.; Elder, D. E.; Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003, 63 (4), 756-759.
74. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66 (3), 1500-1508.
75. Madhunapantula, S. V.; Mosca, P. J.; Robertson, G. P. The Akt signaling pathway: An emerging therapeutic target in malignant melanoma. Cancer Biol. Ther. 2011, 12 (12).
76. Cho, D. C.; Hutson, T. E.; Samlowski, W.; Sportelli, P.; Somer, B.; Richards, P.; Sosman, J. A.; Puzanov, I.; Michaelson, M. D.; Flaherty, K. T.; Figlin, R. A.; Vogelzang, N. J. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012.
77. Yap, T. A.; Yan, L.; Patnaik, A.; Fearen, I.; Olmos, D.; Papadopoulos, K.; Baird, R. D.; Delgado, L.; Taylor, A.; Lupinacci, L.; Riisnaes, R.; Pope, L. L.; Heaton, S. P.; Thomas, G.; Garrett, M. D.; Sullivan, D. M.; de Bono, J. S.; Tolcher, A. W. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29 (35), 4688-4695.
78. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8 (4), 393-412.
79. Mallon, R.; Feldberg, L. R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Santos, E. D.; Chen, Z.; dos Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res. 2011, 17 (10), 3193-3203.
80. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.; Valero, V.; Guzman, M.; Botero, M. L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J. L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68 (19), 8022-8030.
81. Crowder, R. J.; Phommaly, C.; Tao, Y.; Hoog, J.; Luo, J.; Perou, C. M.; Parker, J. S.; Miller, M. A.; Huntsman, D. G.; Lin, L.; Snider, J.; Davies, S. R.; Olson, J. A. Jr.; Watson, M. A.; Saporita, A.; Weber, J. D.; Ellis, M. J. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009, 69 (9), 3955-3962.
82. Engelman, J. A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A. R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S. A.; Song, Y.; Chirieac, L. R.; Kaur, R.; Lightbown, A.; Simendinger, J.; Li, T.; Padera, R. F.; Garcia-Echeverria, C.; Weissleder, R.; Mahmood, U.; Cantley, L. C.; Wong, K. K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14 (12), 1351-1356.
83. Schnell, C. R.; Stauffer, F.; Allegrini, P. R.; O'Reilly, T.; McSheehy, P. M.; Dartois, C.; Stumm, M.; Cozens, R.; Littlewood-Evans, A.; Garcia-Echeverria, C.; Maira, S. M. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008, 68 (16), 6598-6607.
84. Doghman, M.; Lalli, E. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol. Cell Endocrinol. 2012, 364 (1-2), 101-104.
85. Lin, S. F.; Huang, Y. Y.; Lin, J. D.; Chou, T. C.; Hsueh, C.; Wong, R. J. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. Plos One 2012, 7 (10), e46726.
86. Mueller, A.; Bachmann, E.; Linnig, M.; Khillimberger, K.; Schimanski, C. C.; Galle, P. R.; Moehler, M. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother. Pharmacol. 2012, 69 (6), 1601-1615.
87. Fokas, E.; Im, J. H.; Hill, S.; Yameen, S.; Stratford, M.; Beech, J.; Hackl, W.; Maira, S. M.; Bernhard, E. J.; McKenna, W. G.; Muschel, R. J. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012, 72 (1), 239-248.
88. Karar, J.; Cerniglia, G. J.; Lindsten, T.; Koumenis, C.; Maity, A. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxiainducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol. Ther. 2012, 13 (11), 1102-1111.
89. Mukherjee, B.; Tomimatsu, N.; Amancherla, K.; Camacho, C. V.; Pichamoorthy, N.; Burma, S. The dual PI3K/mTOR inhibitor NVPBEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia 2012, 14 (1), 34-43.
90. Cerniglia, G. J.; Karar, J.; Tyagi, S.; Christofidou-Solomidou, M.; Rengan, R.; Koumenis, C.; Maity, A. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol. Pharmacol. 2012, 82 (6), 1230-1240.
91. Fokas, E.; Yoshimura, M.; Prevo, R.; Higgins, G.; Hackl, W.; Maira, S. M.; Bernhard, E. J.; McKenna, W. G.; Muschel, R. J. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat. Oncol. 2012, 7, 48.
92. Li, H.; Jin, X.; Zhang, Z.; Xing, Y.; Kong, X. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem. Funct. 2012.
93. Seitz, C.; Hugle, M.; Cristofanon, S.; Tchoghandjian, A.; Fulda, S. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal crosstalk. Int. J. Cancer. 2012.
94. Schult, C.; Dahlhaus, M.; Glass, A.; Fischer, K.; Lange, S.; Freund, M.; Junghanss, C. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res. 2012, 32 (2), p. 463-474.
95. Kim, A.; Park, S.; Lee, J. E.; Jang, W. S.; Lee, S. J.; Kang, H. J.; Lee, S. S. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk. Res. 2012, 36 (7), 912-920.
96. Marone, R.; Erhart, D.; Mertz, A. C.; Bohnacker, T.; Schnell, C.; Cmiljanovic, V.; Stauffer, F.; Garcia-Echeverria, C.; Giese, B.; Maira, S. M.; Wymann, M. P. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res. 2009, 7 (4), p. 601-613.
97. Aziz, S. A.; Jilaveanu, L. B.; Zito, C.; Camp, R. L.; Rimm, D. L.; Conrad, P.; Kluger, H. M. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res. 2010, 16 (24), 6029-6039.
98. Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (52), 22299-22304.
99. Villanueva, J.; Vultur, A.; Lee, J. T.; Somasundaram, R.; Fukunaga-Kalabis, M.; Cipolla, A. K.; Wubbenhorst, B.; Xu, X.;. Gimotty, P. A; Kee, D.; Santiago-Walker, A. E.; Letrero, R.; D'Andrea, K.; Pushparajan, A.; Hayden, J. E.; Brown, K. D.; Laquerre, S.; McArthur, G. A.; Sosman, J. A.; Nathanson, K. L.; Herlyn, M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010, 18 (6), 683-695.
100. Shi, H.; Kong, X.; Ribas, A.; Lo, R. S. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011, 71 (15), 5067-5074.
101. Civallero, M.; Cosenza, M.; Marcheselli, L.; Pozzi, S.; Sacchi, S. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opin. Investig. Drugs 2012, 21 (11), 1597-1606.
102. Nyfeler, B.; Chen, Y.; Li, X.; Pinzon-Ortiz, M.; Wang, Z.; Reddy, A.; Pradhan, E.; Das, R.; Lehar, J.; Schlegel, R.; Finan, P. M.; Cao, Z. A.; Murphy, L. O.; Huang, A. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. Plos One 2012, 7 (11), e48548.